IL157940A0 - Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient - Google Patents

Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient

Info

Publication number
IL157940A0
IL157940A0 IL15794002A IL15794002A IL157940A0 IL 157940 A0 IL157940 A0 IL 157940A0 IL 15794002 A IL15794002 A IL 15794002A IL 15794002 A IL15794002 A IL 15794002A IL 157940 A0 IL157940 A0 IL 157940A0
Authority
IL
Israel
Prior art keywords
triazaspiro
active ingredient
drugs containing
undecane derivatives
undecane
Prior art date
Application number
IL15794002A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL157940A0 publication Critical patent/IL157940A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15794002A 2001-03-19 2002-03-18 Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient IL157940A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001079611 2001-03-19
PCT/JP2002/002553 WO2002074769A1 (fr) 2001-03-19 2002-03-18 Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane

Publications (1)

Publication Number Publication Date
IL157940A0 true IL157940A0 (en) 2004-03-28

Family

ID=18936022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15794002A IL157940A0 (en) 2001-03-19 2002-03-18 Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient

Country Status (17)

Country Link
US (1) US7285552B2 (pt)
EP (1) EP1378509A4 (pt)
JP (1) JPWO2002074769A1 (pt)
KR (1) KR20030093248A (pt)
CN (1) CN1533390A (pt)
BR (1) BR0208229A (pt)
CA (1) CA2441162A1 (pt)
CZ (1) CZ20032532A3 (pt)
HU (1) HUP0400241A2 (pt)
IL (1) IL157940A0 (pt)
MX (1) MXPA03008528A (pt)
NO (1) NO20034149L (pt)
NZ (1) NZ528270A (pt)
PL (1) PL364469A1 (pt)
RU (1) RU2003128075A (pt)
WO (1) WO2002074769A1 (pt)
ZA (1) ZA200307318B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1619194A3 (en) 2001-03-19 2006-06-07 Ono Pharmaceutical Co., Ltd. Triazaspiro¬5.5|undecane derivatives and pharmaceutical composition comprising the same as active ingredient
AU2003272879A1 (en) * 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
EP1541573A4 (en) * 2002-09-18 2007-05-02 Ono Pharmaceutical Co NEW CRYSTALS OF DERIVATIVE TRIAZASPIRO 5.5 | UNDECANES
AU2003289329A1 (en) * 2002-12-13 2004-07-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist binding to strong binding site of chemokine receptor
JPWO2004094424A1 (ja) * 2003-04-21 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその用途
EP1790639B1 (en) * 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclic compounds and their use as cxcr4-antagonists
CA2586384A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
SG193149A1 (en) 2008-08-11 2013-09-30 Glaxosmithkline Llc Novel adenine derivatives
EP2324025A1 (en) 2008-08-11 2011-05-25 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
PT2534149E (pt) 2010-02-10 2014-12-23 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]oxi}-9-[5-(1- piperidinil)pentil]-7,9-di-hidro-8h-purin-8-ona
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びｈｉｖを治療するための方法
ES2632443T3 (es) 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
US9163023B2 (en) 2012-07-12 2015-10-20 Viiv Healthcare Uk Limited Compounds and methods for treating HIV
CN106029668B (zh) 2014-02-20 2018-02-23 葛兰素史克知识产权第二有限公司 吡咯并[3,2]嘧啶衍生物作为人类干扰素诱导剂
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
UY36758A (es) 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
BR112017028456A2 (pt) 2015-07-02 2018-08-28 Glaxosmithkline Ip Dev Ltd composto, e, método de prevenção e/ou tratamento de hiv
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
CN108368071A (zh) 2015-09-24 2018-08-03 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的化合物
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
US10583140B2 (en) 2016-01-27 2020-03-10 Glaxosmithkline Intellectual Property Development Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
US10981901B1 (en) 2016-04-07 2021-04-20 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US10975287B2 (en) 2016-04-07 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
PE20190106A1 (es) 2016-05-05 2019-01-15 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
WO2019087016A1 (en) 2017-10-30 2019-05-09 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
US20200407393A1 (en) 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
EP3774775B8 (en) 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220117993A1 (en) 2018-08-09 2022-04-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
WO2020044257A1 (en) 2018-08-30 2020-03-05 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
EP4342473A3 (en) 2018-11-30 2024-05-15 GlaxoSmithKline Intellectual Property Development Limited Compounds useful in hiv therapy
MA55200A (fr) 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021024114A1 (en) 2019-08-08 2021-02-11 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
US20220298160A1 (en) 2019-08-28 2022-09-22 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
EP4298105A1 (en) 2021-02-23 2024-01-03 VIIV Healthcare Company Compounds useful in hiv treatment
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS231227B1 (en) 1982-10-01 1984-10-15 Evzen Kasafirek 2,5-pierazindion derivatives
WO1993013101A1 (en) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
BR0016111A (pt) 1999-12-03 2003-03-25 Ono Pharmaceutical Co Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo
FR2804882B1 (fr) 2000-02-11 2002-05-10 Air Liquide Procede de compression d'air atmospherique
EP1619194A3 (en) 2001-03-19 2006-06-07 Ono Pharmaceutical Co., Ltd. Triazaspiro¬5.5|undecane derivatives and pharmaceutical composition comprising the same as active ingredient

Also Published As

Publication number Publication date
HUP0400241A2 (hu) 2004-06-28
JPWO2002074769A1 (ja) 2004-07-08
US7285552B2 (en) 2007-10-23
MXPA03008528A (es) 2004-06-30
BR0208229A (pt) 2004-03-09
CZ20032532A3 (en) 2004-03-17
EP1378509A1 (en) 2004-01-07
CA2441162A1 (en) 2002-09-26
EP1378509A4 (en) 2009-03-25
US20040106619A1 (en) 2004-06-03
NZ528270A (en) 2005-10-28
CN1533390A (zh) 2004-09-29
KR20030093248A (ko) 2003-12-06
NO20034149L (no) 2003-11-19
NO20034149D0 (no) 2003-09-17
RU2003128075A (ru) 2005-04-10
PL364469A1 (en) 2004-12-13
ZA200307318B (en) 2004-07-29
WO2002074769A1 (fr) 2002-09-26

Similar Documents

Publication Publication Date Title
IL157940A0 (en) Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
PL376154A1 (en) Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
HUP0204170A3 (en) 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
IL160707A0 (en) 1, 8-naphthyridine derivatives as antidiabetics
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
MXPA03006775A (es) Formulacion farmaceutica.
AU2002226674A1 (en) Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
MXPA03007641A (es) Formulacion farmaceutica.
HK1042245A1 (en) Pharmaceutical moxifloxacin preparation.
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
PL367179A1 (en) 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
AU4431400A (en) Anticancer agents containing ep1 antagonists as the active ingredient
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
ZA200203311B (en) Pharmaceutical carrier formulation.
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
ZA200307167B (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient.